Research programme: myelosuppression therapy - Biothera

Drug Profile

Research programme: myelosuppression therapy - Biothera

Alternative Names: Imprime WGP

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biothera
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Myelosuppression

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Myelosuppression in USA (PO)
  • 18 Sep 2006 Biothera has been awarded a SBIR grant for the treatment of acute radiation exposure with Imprime WGP™
  • 25 Oct 2005 Preclinical trials in Myelosuppression in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top